Enhanced dissolution rate of celecoxib using PVP and/or HPMC-based solid dispersions prepared by spray drying method

Journal of Pharmaceutical Investigation

Volumn 43, Issue 3, 2013, Pages 205-213

  Lee, Jung Hwan ^a   Kim, Min Jeong ^a   Yoon, Hyeon ^a   Shim, Cho Rok ^a   Ko, Hyun Ah ^a   Cho, Sun Ah ^a   Lee, Dongwon ^a   Khang, Gilson ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Amorphous; Celecoxib; Encapsulation; Solid dispersion; Spray drying; Water soluble polymer

Indexed keywords

CELECOXIB; POVIDONE; SULFONAMIDE;

ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; ENCAPSULATION; HYDROGEN BOND; INFRARED SPECTROSCOPY; MORPHOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PRODUCTIVITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; THERMAL ANALYSIS; THERMOGRAPHY;

EID: 84878626156     PISSN: 20935552     EISSN: 20936214     Source Type: Journal    
DOI: 10.1007/s40005-013-0067-2     Document Type: Article

References (29)

1. Ahn YS, Lee HY, Hong KD, Jung SB, Cho SH, Rhee JM, Lee HB, Khang G (2004) Preparation and in vitro test of solid dispersion using acyclovir and water soluble polymer. J Korean Pharm Sci 34: 169-176.
2. Axelsson H, Lonnroth C, Andersson M, Lundholm K (2010) Mechanisms behind COX-1 and COX-2 inhibition of tumor growth in vivo. Int J Oncol 37: 1143-1152.
3. Boghra RJ, Kothawade PC, Belgamwar VS, Nerkar PP, Tekade AR, Surana SJ (2011) Solubility, dissolution rate and bioavailability enhancement of irbesartan by solid dispersion technique. Chem Pharm Bull (Tokyo) 59: 438-441.
4. Chokshi RJ, Sandhu HK, Iyer RM, Shah NH, Malick AW, Zia H (2005) Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion process as a means to manufacture solid dispersion/solution. J Pharm Sci US 94: 2463-2474.
5. Colin R (1991) Gastrointestinal complications of nonsteroidal antiinflammatory drugs. Schweiz Med Wochenschr 121: 716-721.
6. Craig DQM (2002) The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 231: 131-144.
7. Cui SM, Zhao CS, Chen DW, He ZG (2005) Self-microemulsifying drug delivery systems (SMEDDS) for improving in vitro dissolution and oral absorption of Pueraria lobata isoflavone. Drug Dev Ind Pharm 31: 349-356.
8. Dolenc A, Kristl J, Baumgartner S, Planinsek O (2009) Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm 376: 204-212.
9. Fukuda N, Higuchi N, Ohno M, Kenmochi H, Sekikawa H, Takada M (1986) Dissolution behavior of prednisolone from solid dispersion systems with cyclodextrins and polyvinylpyrrolidone. Chem Pharm Bull 34: 1366-1369.
10. Goldenberg MM (1999) Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther 21: 1497-1513; discussion 1427-1498.
11. Hoozemans JJM, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P (2008) Cyclooxygenase-1 and-2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des 14: 1419-1427.
12. Ishikawa T, Watanabe Y, Takayama K, Endo H, Matsumoto M (2000) Effect of hydroxypropylmethylcellulose (HPMC) on the release profiles and bioavailability of a poorly water-soluble drug from tablets prepared using macrogol and HPMC. Int J Pharm 202: 173-178.
13. Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D (2007) Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm 66: 334-347.
14. Kavanagh N, Corrigan OI (2004) Swelling and erosion properties of hydroxypropylmethylcellulose (Hypromellose) matrices-influence of agitation rate and dissolution medium composition. Int J Pharm 279: 141-152.
15. Konno H, Handa T, Alonzo DE, Taylor LS (2008) Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm 70: 493-499.
16. Kubo Y, Yagi N, Sekikawa H (2011) Stability of probucol-polyvinylpyrrolidone solid dispersion systems. Yakugaku Zasshi 131: 629-634.
17. Lee JH, Ku J, Park JS, Park JH, Ahn SI, Mo JH, Kim YT, Rhee JM, Lee HB, Khang G (2008) Improved dissolution and characterization of solid dispersed atorvastatin calcium. J Korean Pharm Sci 38: 111-117.
18. Luu CD, Foo H, Crewther SG, Crewther DP (2001) Effects of a non-steroidal (ketorolac tromethamine) and a steroidal (dexamethasone) anti-inflammatory drug on refractive state and ocular growth. Clin Exp Ophthalmol 29: 175-178.
19. Manojlovic V, Bunjes KWV, Neubc A, Schubert R, Bugarski B, Leneweit G (2008) Membrane interactions of ternary phospholipid/cholesterol bilayers and encapsulation efficiencies of a RIP II protein. Colloid Surf B 64: 284-296.
20. Meyer JD, Manning MC, Carpenter JF (2004) Effects of potassium bromide disk formation on the infrared spectra of dried model proteins. J Pharm Sci 93: 496-506.
21. Paradkar A, Ambike AA, Jadhav BK, Mahadik KR (2004) Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int J Pharm 271: 281-286.
22. Paudel A, Worku ZA, Meeus J, Guns S, van den Mooter G (2012) Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int J Pharm. doi: 10. 1016/j. ijpharm. 2012. 07. 015.
23. Paulson SK, Kaprak TA, Gresk CJ, Fast DM, Baratta MT, Burton EG, Breau AP, Karim A (1999) Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm Drug Dispos 20: 293-299.
24. Rose MJ, Woolf EJ, Matuszewski BK (2000) Determination of celecoxib in human plasma by normal-phase high-performance liquid chromatography with column switching and ultraviolet absorbance detection. J Chromatogr B 738: 377-385.
25. Seong H, Moon DS, Khang G, Lee JS (2002) Preparation of BCNU-loaded PLGA wafers and in vitro release behavior. Polymer (Korea) 26: 128-138.
26. Shi S, Klotz U (2008) Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 64: 233-252.
27. Urbanetz NA, Lippold BC (2005) Solid dispersions of nimodipine and polyethylene glycol 2000: dissolution properties and physico-chemical characterisation. Eur J Pharm Biopharm 59: 107-118.
28. Won DH, Kim MS, Lee S, Park JS, Hwang SJ (2005) Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int J Pharm 301: 199-208.
29. Yazdanian M, Briggs K, Jankovsky C, Hawi A (2004) The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm Res 21: 293-299.